https://www.selleckchem.com/products/ikk-16.html
Colorectal cancer (CRC) affects many older adults. We investigated the efficacy and safety of adding anti-epidermal growth factor receptor (EGFR) agents to doublet chemotherapy (DC) in older patients. Patients with RAS wild-type (WT) metastatic CRC (mCRC) receiving first-line DC+anti-EGFR (n=1191) or DC alone (n=729) from seven trials in the Aide de Recherche en Cancerologie Digestive database were included. The prognostic and predictive effects of age were investigated. Progression-free and overall survival (OS) were evaluated between a
Gefällt mir
Kommentar
Teilen
